Brief: Spectrum Pharmaceuticals Submits New Drug Application For Poziotinib
06/12/2021 12:36
Dec 6 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR
POZIOTINIB
* SPECTRUM - NDA SUBMISSION IS BASED ON POSITIVE RESULTS OF
COHORT
2 FROM ZENITH20 CLINICAL TRIAL, WHICH ASSESSED SAFETY AND
EFFICACY OF POZIOTINIB
* SPECTRUM PHARMACEUTICALS - PRODUCT HAS RECEIVED FAST TRACK
DESIGNATION
Source text for Eikon: ID:nBw8zd3CXa
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary